Picture of neon light reading 'Open'

Discover open research at Strathprints as part of International Open Access Week!

23-29 October 2017 is International Open Access Week. The Strathprints institutional repository is a digital archive of Open Access research outputs, all produced by University of Strathclyde researchers.

Explore recent world leading Open Access research content this Open Access Week from across Strathclyde's many research active faculties: Engineering, Science, Humanities, Arts & Social Sciences and Strathclyde Business School.

Explore all Strathclyde Open Access research outputs...

Salicylanilide inhibitors of toxoplasma gondii

Fomovska, Alina and Wood, Richard and Mui, E. and Dubey, J.P. and Ferreira, Leandra and Hickman, Mark and Lee, Patricia and Leed, Susan and Auschwitz, Jennifer and Welsh, William and Sommerville, Caroline and Woods, Stuart and Roberts, Craig and Mcleod, Rima (2012) Salicylanilide inhibitors of toxoplasma gondii. Journal of Medicinal Chemistry, 55 (19). pp. 8375-8391. ISSN 0022-2623

Full text not available in this repository. Request a copy from the Strathclyde author

Abstract

Toxoplasma gondii ( T. gondii ) is an apicomplexan parasite that can cause eye disease, brain disease, and death, especially in congenitally infected and immune-compromised people. Novel medicines effective against both active and latent forms of the parasite are greatly needed. The current study focused on the discovery of such medicines by exploring a family of potential inhibitors whose antiapicomplexan activity has not been previously reported. Initial screening efforts revealed that niclosamide, a drug approved for anthelmintic use, possessed promising activity in vitro against T. gondii . This observation inspired the evaluation of the activity of a series of salicylanilides and derivatives. Several inhibitors with activities in the nanomolar range with no appreciable in vitro toxicity to human cells were identified. An initial structure-activity relationship was explored. Four compounds were selected for evaluation in an in vivo model of infection, and two derivatives with potentially enhanced pharmacological parameters demonstrated the best activity profiles.